UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000025560 |
|---|---|
| Receipt number | R000029360 |
| Scientific Title | A multicenter, phase 1/2 study of Ramucirumab plus Nivolumab as second-line therapy in participants with gastric or GEJ cancer |
| Date of disclosure of the study information | 2017/01/06 |
| Last modified on | 2022/11/28 17:30:30 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/01/06 13:34:14 | ||
| 2 | Update | 2017/06/21 18:10:54 | Recruitment status |
|
| 3 | Update | 2018/01/16 18:56:24 | Recruitment status |
|
| 4 | Update | 2019/01/11 18:06:13 | Last follow-up date Date analysis concluded |
|
| 5 | Update | 2020/04/24 17:06:44 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Address Address Department Organization Organization Address Address Tel |
|
| 6 | Update | 2020/04/24 17:36:55 | Date of IRB Last follow-up date Date analysis concluded |
|
| 7 | Update | 2020/04/24 17:37:39 | Division name |
|
| 8 | Update | 2020/04/24 18:07:57 | Division name Institute |
|
| 9 | Update | 2021/06/25 10:09:40 | Division name Division name |
|
| 10 | Update | 2021/06/25 10:10:18 | Date analysis concluded |
|
| 11 | Update | 2021/10/15 14:16:53 | Date analysis concluded |
|
| 12 | Update | 2022/03/18 11:03:34 | Recruitment status |
|
| 13 | Update | 2022/11/28 17:30:30 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
